<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619653</url>
  </required_header>
  <id_info>
    <org_study_id>MYOFLAME-19</org_study_id>
    <secondary_id>2022-001682-12</secondary_id>
    <nct_id>NCT05619653</nct_id>
  </id_info>
  <brief_title>Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19</brief_title>
  <acronym>MYOFLAME-19</acronym>
  <official_title>Randomised Placebo Controlled Clinical Trial of Efficacy of MYOcardial Protection in Patients With Postacute inFLAMmatory Cardiac involvEment Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valentina Puentmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcedis GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications and&#xD;
      are defined by lingering symptoms, not present prior to the infection, typically persisting&#xD;
      for more than 4 weeks. Cardiac symptoms due to post-acute inflammatory cardiac involvement&#xD;
      affect a broad segment of people, who were previously well and may have had only mild acute&#xD;
      illness (PASC-cardiovascular syndrome, PASC-CVS). Symptoms may be contiguous with the acute&#xD;
      illness, however, more commonly they occur after a delay. Symptoms related to the&#xD;
      cardiovascular system include exertional dyspnoea, exercise intolerance chest tightness,&#xD;
      pulling or burning chest pain, and palpitations. Phenotypically, it is characterised by&#xD;
      chronic perivascular and myopericardial inflammation. Cardiac symptoms may be accompanied by&#xD;
      manifestations of other organ systems, including fatigue, brain fog, myalgias, skin and joint&#xD;
      manifestations, etc, now commonly referred to as the Long COVID or PASC syndrome.&#xD;
&#xD;
      Early intervention with immunosuppression and antiremodelling therapy may reduce symptoms and&#xD;
      myocardial impairment, by minimising the disease activity and inducing disease remission. Low&#xD;
      dose maintenance therapy may help to maintain the disease activity at the lowest possible&#xD;
      level. Clinical trials of immunosuppression in patients with viral myocarditis in advanced&#xD;
      stages of heart failure have not shown an improved outcome, however there was an improvement&#xD;
      of LVEF with antiremodelling therapy in patients with reduced function. The benefits of early&#xD;
      initiations of antiremodelling therapy to reduce symptoms of exercise intolerance are well&#xD;
      recognised, but not commonly employed outside the contexts of heart failure or hypertension.&#xD;
      As most patients with inflammatory heart disease only have mild and nonspecific symptoms and&#xD;
      few or no structural abnormalities, they are left untreated (standard of care). The aim of&#xD;
      this study is to examine the efficacy of a combined immunosuppressive/antiremodelling therapy&#xD;
      in patients with PASC symptoms and inflammatory cardiac involvement determined by CMR, to&#xD;
      reduce the symptoms and inflammatory myocardial injury and thereby stop the progression to&#xD;
      reduced LVEF, HF and death.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicentre randomised double-blind, placebo-controlled clinical trial 1:1 randomisation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>16 weeks</time_frame>
    <description>absolute change of LVEF from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar burden by late gadolinium enhancement (LGE)</measure>
    <time_frame>16 weeks</time_frame>
    <description>absolute change of LGE from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise testing (CPET)</measure>
    <time_frame>16 weeks</time_frame>
    <description>absolute change of achieved VO2max from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean T1 and T2 mapping</measure>
    <time_frame>16 Weeks</time_frame>
    <description>absolute change in T1 and T2 mapping values (ms) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV mass (g/m2)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>absolute change of measures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV strain %</measure>
    <time_frame>16 Weeks</time_frame>
    <description>absolute change of measures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic stiffness (PWV)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>absolute change of measures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic wall imaging (LGE)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>absolute change of measures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Symptom Score (RAND 36)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>change thereof compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF and MACE Endpoints</measure>
    <time_frame>1 and 5 years</time_frame>
    <description>proportion of patients with endpoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Myocardial Inflammation</condition>
  <condition>Remodeling, Left Ventricle</condition>
  <condition>Remodeling, Vascular</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Exercise Intolerance</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone and Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 and Placebo 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>randomised double-blind, placebo-controlled clinical trial 1:1 randomisation</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>randomised double-blind, placebo-controlled clinical trial 1:1 randomisation</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years&#xD;
&#xD;
          -  Patients with documented recent COVID19 infection (&gt;4 weeks and &lt;6 months)&#xD;
&#xD;
          -  PASC Syndrome, defined by persistence or new symptoms, not present prior to the&#xD;
             infection.&#xD;
&#xD;
          -  CMR evidence of inflammatory cardiac involvement at BL by any of the following&#xD;
             criteria:&#xD;
&#xD;
          -  Increased native T1≥ 1130 ms at 3.0 Tesla (or 1030 ms at 1.5 Tesla) and/or;&#xD;
&#xD;
          -  Increased native T2 ≥39.5 ms at 3.0 Tesla (or 49.5 at 1.5 Tesla) and/or&#xD;
&#xD;
          -  present non-ischaemic myopericardial LGE and/or;&#xD;
&#xD;
          -  LVEF ≥45 - ≤50%.&#xD;
&#xD;
          -  Willingness to comply with the study procedures and study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe acute COVID illness requiring hospitalisation&#xD;
&#xD;
          -  Known allergy to or intolerance of the study medications&#xD;
&#xD;
          -  Symptomatic hypotension (systolic blood pressure less than 90 mm Hg), not reversible&#xD;
             with oral hydration&#xD;
&#xD;
          -  Any previous or current use of ACE inhibitors, AR Blockers&#xD;
&#xD;
          -  Any previous oral prednisolone, or any other immunosuppressive or biological treatment&#xD;
             (within 6 months)&#xD;
&#xD;
          -  History or CMR evidence of pre-existing significant heart disease, including:&#xD;
&#xD;
               1. Known cardiac impairment with LVEF ≤44%&#xD;
&#xD;
               2. Congestive heart failure (NYHA III-IV)&#xD;
&#xD;
               3. Active heart failure treatment&#xD;
&#xD;
               4. Established ischaemic heart disease, peripheral arterial disease and/or&#xD;
                  cerebrovascular disease&#xD;
&#xD;
               5. Persistent or permanent atrial fibrillation or significant heart rhythm&#xD;
                  abnormalities&#xD;
&#xD;
               6. Congenital or clinically relevant valvular heart disease (moderate or severe)&#xD;
&#xD;
               7. Specific cardiomyopathy (hypertrophic, hypertensive heart disease, amyloidosis,&#xD;
                  previous myocarditis, non-ischaemic dilated cardiomyopathy, arrhythmogenic right&#xD;
                  ventricular cardiomyopathy, non-compaction cardiomyopathy, etc).&#xD;
&#xD;
          -  Known significant concomitant diseases that are likely to interfere with the&#xD;
             evaluation of the patient's safety and of the study outcome (e.g. diabetes, lung or&#xD;
             hepatic disease, epilepsy, psychiatric disorders, renal disease with a current&#xD;
             estimated GFR &lt;30 mL/min/1.73 m² using MDRD formula, chronic systemic infection or&#xD;
             immunocompromise)&#xD;
&#xD;
          -  Exceeding scanner bore and table-holding capacity: Weight &gt;125 kg, BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Contraindications to contrast-enhanced CMR imaging, e.g.&#xD;
&#xD;
               1. MR-unsafe implantable device&#xD;
&#xD;
               2. known allergy to gadolinium-based contrast agent (CBGA)&#xD;
&#xD;
          -  For female participants:&#xD;
&#xD;
               1. Pregnant or breastfeeding women&#xD;
&#xD;
               2. Persons of childbearing potential not willing to use effective contraception&#xD;
                  (defined as PEARL index &lt;1 - e.g. contraceptive pill, IUD)&#xD;
&#xD;
          -  Known alcohol, drug or chemical abuse&#xD;
&#xD;
          -  Patients currently participating in an investigational study or for whom participation&#xD;
             is planned.&#xD;
&#xD;
          -  Unable to provide written informed consent&#xD;
&#xD;
        Patients with CMR evidence of structural heart disease or incidental heart rhythm&#xD;
        abnormalities will be advised to see their own doctor for further investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Puntmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eike Nagel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentina Puntmann, MD, PhD</last_name>
    <phone>‭+4969630189441‬</phone>
    <email>CVI-Myoflame@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for experimental and translational cardiovascular imaging</name>
      <address>
        <city>Frankfurt Am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eike Nagel, MD, PhD</last_name>
      <phone>‭+49 69 630189441‬</phone>
      <email>CVI-Myoflame@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Weis</last_name>
      <phone>‭+49 69 630189441‬</phone>
      <email>CVI-Myoflame@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Eike Nagel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Puntmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cardiac-imaging.org/myoflame-19.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu E, Vanchin B, Holm N, Karyou A, Laux GS, Arendt C, De Leuw P, Zacharowski K, Khodamoradi Y, Vehreschild MJGT, Rohde G, Zeiher AM, Vogl TJ, Schwenke C, Nagel E. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022 Oct;28(10):2117-2123. doi: 10.1038/s41591-022-02000-0. Epub 2022 Sep 5.</citation>
    <PMID>36064600</PMID>
  </reference>
  <reference>
    <citation>Writing Committee; Gluckman TJ, Bhave NM, Allen LA, Chung EH, Spatz ES, Ammirati E, Baggish AL, Bozkurt B, Cornwell WK 3rd, Harmon KG, Kim JH, Lala A, Levine BD, Martinez MW, Onuma O, Phelan D, Puntmann VO, Rajpal S, Taub PR, Verma AK. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 May 3;79(17):1717-1756. doi: 10.1016/j.jacc.2022.02.003. Epub 2022 Mar 16. No abstract available.</citation>
    <PMID>35307156</PMID>
  </reference>
  <reference>
    <citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Nov 1;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557. Erratum In: JAMA Cardiol. 2020 Nov 1;5(11):1308.</citation>
    <PMID>32730619</PMID>
  </reference>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>December 13, 2022</last_update_submitted>
  <last_update_submitted_qc>December 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Valentina Puentmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

